Abstract Previous studies have shown that CCL2 (C–C motif chemokine ligand 2) induces chronic pain, but the exact mechanisms are still unknown. Here, we established models to explore the potential mechanisms. Behavioral experiments revealed that an antagonist of extracellular signal-regulated kinase (ERK) inhibited not only CCL2-induced inflammatory pain, but also pain responses induced by complete Freund’s adjuvant. We posed the question of the intracellular signaling cascade involved. Subsequent experiments showed that CCL2 up-regulated the expression of phosphorylated ERK (pERK) and N-methyl D-aspartate receptor [NMDAR] subtype 2B (GluN2B); meanwhile, antagonists of CCR2 and ERK effectively reversed these phenomena. Whole-cell patchclamp recordings revealed that CCL2 enhanced the NMDAR-induced currents via activating the pERK pathway, which was blocked by antagonists of GluN2B and ERK. In summary, we demonstrate that CCL2 directly interacts with CCR2 to enhance NMDAR-induced currents, eventually leading to inflammatory pain mainly through the CCL2–CCR2–pERK–GluN2B pathway.

Keywords C-C motif chemokine ligand 2 · Monocyte chemoattractant protein 1 · Neuron-glial interaction · Extracellular signal-regulated kinase

Introduction

Most known inflammatory mediators cause pain by binding to nociceptors located in the peripheral nervous system [1–3]. Recently, it has been recognized that neuroinflammation plays a key role in the pathogenesis of neuropathic and inflammatory pain [4, 5]. Increasing evidence suggests that microglia play important roles in the development and progression of chronic pain [6, 7]. Microglia can be rapidly activated by small pathological changes in the central nervous system.

Chemokines are a family of secreted small molecules that regulate inflammatory responses in the dorsal root ganglia, spinal cord, and brain [5, 8–10]. Increasing evidence suggests that chemokines are associated with chronic pain after nerve injury [11, 12] and chronic itch [13]. C-C motif chemokine ligand 2 (CCL2; also known as monocyte chemotactic protein 1) specifically recruits monocytes to the sites of inflammation, infection, or trauma. Evidences have suggested that CCL2 and CCR2 (CC receptor 2) are involved in neuropathic pain [14, 15].
Intrathecal injection of CCL2 causes inflammatory hyperalgesia [16]. A significant reduction in mechanical allodynia occurs after partial ligation of the sciatic nerve in mice lacking CCR2 [17, 18]. However, the cellular mechanism of CCL2-induced pain sensitization is entirely not clear. Our previous research showed that CCL2 directly regulates the synaptic plasticity of excitatory neurons expressing CCR2 in spinal cord outer lamina II (IIo), and this is the basis of the central sensitization in chronic pain [16]. However, some issues still need to be further clarified, such as: the downstream pathway of CCL2/CCR2; the molecules through which CCL2/CCR2 regulates NMDARs; and the selective specific signaling pathway through which CCL2/CCR2 regulates NMDARs. Using patch-clamp recordings together with biochemical and behavioral assays, we demonstrated that upon peripheral inflammation or injury, released CCL2 directly acts on CCR2 in superficial dorsal horn neurons, leading to activation of ERK signals and GluN2B upregulation, which in turn contribute to the development of inflammatory pain.

Methods

Animals and Pain Models

C57Bl/6 background wild-type (WT) mice were purchased and bred in the Animal Facility of the Fourth Military Medical University. Young C57Bl/6 mice (4–6 weeks old) were used for electrophysiological studies in spinal cord slices, and adult CD1 and C57Bl/6 mice (male, 8–10 weeks old) were used for behavioral and pharmacological experiments. All the animal procedures were approved by the Animal Care Committee of the Fourth Military Medical University. To produce persistent inflammatory pain, complete Freund's adjuvant (CFA, 20 μL, 1 mg/mL, Sigma, St Louis, MO, USA) was injected into the plantar surface of a hind paw.

Behavioral Analysis

Mice were habituated to the testing environment for at least 2 days before baseline testing. Thermal hyperalgesia and mechanical allodynia were tested as previously described [16, 19]. The experimenters were blinded to treatments.

Western Blot

Protein samples were prepared in the same way as for ELISA analysis; they were separated on SDS-PAGE gels and transferred to nitrocellulose blots. The blots were blocked and incubated overnight at 4°C with antibodies against ERK, GluN1, and GluN2B (1:50, rabbit; Boster, Fremont, CA), GluN2A (1:500, rabbit, Abcam, Cambridge, MA), and CCL2 and CCR2 (1:500, rabbit; Novus Biologicals, Centennial, CO).

Spinal Cord Slice Preparation and Patch-Clamp Recordings

As we previously reported [16], the Krebs' solution contained (in mmol/L): 117 NaCl, 3.6 KCl, 2.5 CaCl₂, 1.2 MgCl₂, 1.2 NaH₂PO₄, 25 NaHCO₃, and 11 glucose. After establishing the whole-cell configuration, neurons were held at −70 mV to record evoked excitatory post-synaptic currents (eEPSCs) by stimulating the dorsal root entry zone via a concentric bipolar electrode using an isolated current stimulator [19]. The internal solution contained (in mmol/L): 110 Cs₂SO₄, 2 KCl, 0.1 CaCl₂, 2 MgCl₂, 1.1 EGTA, 10 HEPES, 5 ATP-Mg. QX-314 (5 mmol/L) was added to the pipette solution to prevent the discharge of action potentials. To induce spinal long-term potentiation (LTP), low-frequency conditioning stimulation (240 pulses at 2 Hz) was applied to the dorsal root with the same intensity as test stimulation. Signals were filtered at 2 kHz and digitized at 5 kHz. Data were stored and analyzed on a personal computer using pCLAMP10 software (Molecular Devices, San Jose, CA).

Reverse-Transcription PCR (RT-PCR)

Total RNA was extracted using TRIzol reagent and was reverse transcribed using an oligo (dT) primer. qPCR analysis was performed with the Real-Time Detection System by SYBR green I dye detection (Takara, Shiga, Kusatsu, Japan).

Immunofluorescence Labelling

Immunohistochemistry was performed according to standard protocols, and the following primary antibodies were used: pERK (rabbit, 1: 200, Cell Signaling, Danvers, MA, USA), Alexa Fluor® 488 (donkey anti-rabbit IgG, 1:1000, Molecular Probes, Waltham, MA), CGRP antibody (goat, 1:300, Abcam, Cambridge, MA), CCR2 antibody (rabbit, 1:300, Novus Biologicals, Centennial, CO, USA), Alexa Fluor® 594 (donkey anti-rabbit IgG, 1:1000, Abcam), pERK antibody (mouse, 1: 300, Abcam), and Alexa Fluor® 594 (donkey anti-mouse IgG, 1:1000, Abcam).

Drugs and Administration

The mitogen-activated protein kinase (MEK1) inhibitor PD98059 (Cell Signaling Technology, EMD Millipore, Billerica, MA, USA), the CCR2 antagonist, RS504393 (Tocris Bioscience, Bristol, UK), CCL2 (R & D Systems,
ERK Mediates CCL2- and CFA-Induced Mechanical Hyperalgesia

To further investigate the mechanism of spinal sensitization induced by CCL2, we tested the behavioral involvement of spinal ERK in CCL2- and CFA-induced hyperalgesia. Consistent with our previous reports [16], intrathecal CCL2 (100 ng) induced rapid mechanical hyperalgesia, characterized by a prominent drop in mechanical threshold, while intrathecal administration of an ERK inhibitor, PD98059 (1 μg), potently abolished this hyperalgesia (Fig. 1B). Intraplantar CFA injection induced marked mechanical hyperalgesia (Fig. 1B) and thermal hyperalgesia (Fig. 1C) on day 1 in C57Bl/6 mice. It is worth noting that the mechanical hyperalgesia was completely reversed by PD98059 (1 μg) at 1 h after intrathecal injection (Fig. 1B) and the thermal hyperalgesia was completely reversed by PD98059 (1 μg) at 3 h after intrathecal injection (Fig. 1C). This reversal was transient and was recovered within 24 h after antagonist treatment (Fig. 1B). Furthermore, intraplantar CFA injection induced significant mechanical hyperalgesia on day 1 in CD1 mice as well (Fig. 1C), and this was remarkably attenuated by RS504393 (20 μg, i.t.), a CCR2 antagonist, at 1 h after injection, and recovered 6 h after antagonist treatment (Fig. 1D), consistent with the results of our previous testing of thermal pain sensitivity [16]. These results indicate that CCL2- and inflammation-mediated mechanical hyperalgesia require the involvement of ERK.

CCL2 Enhances NMDA Currents in Spinal Dorsal Horn Neurons via ERK Activation

Previous studies have shown that CCL2 enhances NMDA currents in spinal dorsal horn neurons [16], so we next sought to identify which pathway mediates this enhancement. Western blotting analysis was performed in the spinal dorsal horn from naïve mice and mice with intrathecal delivery of CCL2 in the absence and presence of PD98059 (1 μg) or RS504393 (20 μg). Compared to naïve mice, intrathecal administration of CCL2 (100 ng) evoked significant upregulation of pERK at 6 h after treatment (Fig. 3A, B). Of note, this exaggerated increase of pERK was significantly depressed by intrathecal delivery of PD98059 and RS504393 (Fig. 3A, B), suggesting the involvement of pERK activation in the CCL2/CCR2 pathway.

In order to confirm the functional role of pERK enhancement, we tested NMDA-induced currents in spinal lamina I0 neurons. As shown in Fig. 3C, CCL2 superfusion caused a marked increase of these currents. Antagonizing CCR2 with RS504393 (50 nmol) significantly suppressed this enhancement, suggesting that CCL2 enhances NMDA function via activation of CCR2. To further determine whether ERK activation links the interaction between CCL2 and inflammation, and both were upregulated. Also, a dramatic increase of the CCL2 and CCR2 mRNA levels was detected in the spinal dorsal horn on day 1 after CFA injection (Fig. 2A). Western blot analysis showed that CFA inflammation led to a significant increase in CCL2 expression as well as CCR2 expression (Fig. 2B, C). CCL2 localization in the spinal cord has been clearly reported in previous studies. For example, CCL2 is mainly localized in lamina II [11, 21], and is also found in some central terminals of primary afferents that express CGRP-IR (calcitonin gene-related peptide immunoreactive) in the superficial spinal cord [15]. Previous immunohistochemical studies have shown CCR2 expression in spinal microglial cells [18], astrocytes [22], and neurons [15]. CCL2 is mainly expressed on isolectin B4-positive and CGRP-positive neurons in dorsal root ganglia [23]. We further assessed the expression of pERK in CGRP-positive primary afferent terminals. Immunofluorescence staining revealed that CFA inflammation caused marked pERK1/2 induction in the dorsal horn, especially in the superficial dorsal horn where nociceptive primary afferents marked by CGRP mainly terminate (Fig. 2D). Also double-staining of CCR2 and pERK1/2 showed a marked increase in co-expressing neurons (Fig. 2D). Meanwhile, western blots showed that CFA resulted in a significant increase in pERK expression (Fig. 2E). These results suggest that peripheral inflammation activates CCL2/CCR2 and the ERK signaling pathway in the superficial dorsal horn.
NMDARs, we included PD98059 in the pipette solution and found that it completely abolished the enhancement of NMDA currents by CCL2 (Fig. 3C, D). We infer from the above that CCL2 enhances NMDAR function via the pERK signaling pathway.

Endogenous CCL2 and CCR2 Are Involved in the Enhancement of NMDA Currents in the Inflammatory State

In addition to the enhancement of NMDA currents by CCL2 in naïve mice, we next addressed whether CCL2 can further increase NMDA currents in inflammatory states. Consistent with previous reports [16], these currents displayed robust upregulation upon CFA inflammation (Fig. 4A, B). Similar to the facilitation of NMDA currents by CCL2 in the naïve state, the increase in currents by inflammation was further enhanced by CCL2 (Fig. 4A, B). Given the fact that peripheral inflammation was able to induce CCL2 expression in the spinal cord, we next asked whether the enhancement of NMDA currents by inflammation is mediated by endogenous CCL2 release. The CFA-induced facilitation of the currents was completely eliminated by blockade of CCR2 with pretreatment of

**Fig. 1** Inhibition of CCL2- and CFA-induced mechanical hyperalgesia by intrathecal injection of RS504393 or PD98059. A Prevention of CCL2 (100 ng, i.t.)-induced mechanical hyperalgesia by PD98059 (1 g, i.t.). B Reversal of CFA-induced mechanical hyperalgesia by PD98059 (1 µg, i.t.) given 1 day after CFA injection. C Reversal of CFA-induced thermal hyperalgesia by PD98059 (1 µg, i.t.) given 1 day after CFA injection. D Reversal of CFA-induced mechanical hyperalgesia by RS504393 (20 µg, i.t.) given 1 day after CFA injection. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n = 5–6.
Fig. 2 CFA induces upregulation of CCL2, CCR2, and ERK activation in the spinal dorsal horn. A Real-time PCR reveals distinct regulation of CCL2 and CCR2 mRNA expression in the spinal cord following inflammation. Both CCL2 and CCR2 are upregulated after inflammatory pain. CFA induces a transient increase in CCL2 and CCR2 mRNA levels on day 1 (**P < 0.01, n = 6–7). B, C Western blots showing that CFA leads to a significant increase in CCL2 and CCR2 expression. D Immunofluorescence staining showing an increase in pERK-immunoreactive (pERK-ir) cells in CCR2-expressing neurons in the ipsilateral (injured) dorsal horn at 24 h after CFA (right panels, enlargement of the white frames; arrows, pERK-ir cells in the superficial dorsal horn). E Western blot showing that CFA results in a significant increase in pERK expression.
RS504393 in spinal lamina IIo neurons (Fig. 4C, D). These results indicate that the endogenous CCL2/CCR2 signaling cascade contributes to enhancement of NMDAR function after paw inflammation.

CCL2 Enhances NMDA Currents via GluN2B Activation and a GluN2B Antagonist Attenuates CFA-Induced Pain Hypersensitivity

To further address how CCR2 works on NMDAR function, we assessed the expression of different subtypes of NMDAR (GluN1, GluN2A, and GluN2B subunits) by western blot analysis. Our results demonstrated that CCL2 led to a dramatic increase in GluN2B expression, but no significant changes in GluN2A and GluN1 expression (Fig. 5A, B), and RS504393 partly abolished the facilitation of GluN2B by CCL2. In support of these results, patch-clamp recording from lamina IIo neurons demonstrated that Ifenprodil, a specific blocker of GluN2B, which partially inhibits NMDA currents in these neurons, abolished the facilitation of NMDA currents produced by CCL2 (Fig. 5C, D). This indicates that CCL2 exerts its major effect on the GluN2B subunit in spinal lamina IIo neurons. Furthermore, we demonstrated that blockade of the GluN2B subunit with Ifenprodil strongly reversed the maintained mechanical allodynia as well as the thermal hyperalgesia induced by CFA inflammation (Fig. 5E, F).

Enhancement of NMDA Currents by CCL2/CCR2 is Mediated via the Cox-2 Pathway

Cox-2 plays an important role in the inflammatory process. To determine which factors activate the CCL2/CCR2 signaling pathway and cause central sensitization, we further tested whether Cox-2 is involved in the CCL2/CCR2-mediated neuroinflammatory response. Perfusion of 50 μmol NMDA at a holding potential of –40 mV induced a robust inward current in WT mice. Superfusion of CCL2 at 100 ng/mL increases NMDA-induced currents (*P < 0.05, n = 6–7), and this is abolished by the antagonist RS504393. The ERK blocker PD98059 in the pipette solution abolishes the enhancement effect of CCL2 on NMDA-induced currents on lamina IIO neurons.

The CCR2 Antagonist RS504393 and ERK Inhibitor PD98059 Abolish Spinal LTP In Vitro

LTP in the spinal dorsal horn is closely associated with the generation and development of chronic pain [24]. To investigate whether LTP is induced at spinal synapses, we recorded eEPSCs in lamina IIO neurons at a holding potential of –70 mV by stimulating dorsal roots in the presence of the γ-aminobutyric acid (A) receptor antagonist gabazine (10 μmol) and the glycine receptor antagonist strychnine (1 μmol). In the lamina IIO neurons of WT mice, conditioning low-frequency stimulation (240 pulses at 2 Hz) at a holding potential of –70 mV induced LTP of monosynaptic C-fiber eEPSCs by >200% at 30 min (Fig. 7A, B). Superfusion of the CCR2 antagonist...
RS504393 abolished the generation of LTP, indicating an essential role of CCR2 in spinal LTP induction (Fig. 7A, B). Meanwhile, this spinal LTP was also blocked by the ERK inhibitor PD98059, suggesting the involvement of ERK activity (Fig. 7A, B).

**Discussion**

The results of the present study lead us to propose the model represented schematically in Fig. 8. Following peripheral inflammation or injury, directly released CCL2 acts on CCR2 in superficial dorsal horn neurons, leading to the activation of ERK signals and GluN2B upregulation, which in turn induces inflammatory pain.

Emerging evidence shows that, during the development of chronic pain, astrocytes regulate synaptic plasticity in the spinal dorsal horn through neuron–glia and glia–neuron interactions [25]. Excessive neuronal activity leads to the activation of glial cells and the release of cytokines and chemokines [26]. CCL2 is involved in the interaction between superficial neurons and non-neurons in the spinal dorsal horn [27]. Previous studies have shown that CCR2 is expressed in spinal microglia [18], astrocytes [22], and neurons [28]. CCR2 up-regulation has also been found in spinal microglia after partial sciatic nerve injury [18] and in astrocytes after spinal cord contusion injury [22]. Our previous reports showed that CCL2 directly regulates the synaptic plasticity of CCR2-expressing excitatory neurons in spinal lamina II, further leading to central sensitization [16]. But the specific downstream pathways of CCL2/CCR2 in superficial neurons of the dorsal horn needed to be further elucidated.

In this study, we further explored the specific downstream mechanism of action of CCL2 on CCR2 in superficial neurons of the spinal dorsal horn. First, the facilitating effect of CCL2 on NMDA-induced currents is dependent on the ERK pathway; second, CCR2 up-regulation in spinal dorsal horn neurons after injury further increases the CCL2 effect and leads to central sensitization; third, CCL2 enhances NMDA currents via GluN2B activation; and finally, ERK is necessary for the induction of spinal LTP by CCL2–CCR2 activation.

Our previous study showed that CCL2 enhances NMDA currents only in CCR2-positive excitatory neurons that express VGLUT2 and excitatory SOM\(^+\) interneurons [16]. These interneurons form a nociceptive circuit by receiving inputs from C fibers that express TRPV1 (transient receptor potential cation channel subfamily V member 1) and sending the output to lamina I projection neurons that are essential for pain transmission [29–31]. Our present study extended this to show that CCL2 promoted NMDAR activity via phosphorylation of ERK, a marker for central sensitization.
Fig. 5 CCL2 enhances NMDA currents via GluN2B activation. A, B Western blots showing that CCL2 induces a significant increase in GluN2B expression. C, D Ifenprodil, a GluN2B blocker, partially inhibits NMDAR-induced currents in lamina IIo neurons and abolishes the CCL2-induced enhancement of these currents. E, F Behavioral tests showing that CFA-induced mechanical allodynia and thermal hyperalgesia are reversed by i.p. Ifenprodil. *P < 0.05, **P < 0.01, n = 6–8.
This provides new research ideas and further drug targets for the treatment of pain. Studies have identified MEK1/2-ERK1/2 signaling as an important intracellular pathway that links Schwann cell mutations to the activation of pathology-associated macrophages in peripheral nerves [34]. Our results further demonstrated that the release of CCL2 in the spinal dorsal horn activated the ERK pathway through CCR2, thereby enhancing NMDAR functions.

Thacker et al. [35] demonstrated that intraspinal CCL2 elicits a massive microglial response in the ipsilateral dorsal horn; however, the role of endogenous CCR2 in inflammation needed to be further verified. Our study showed that CCR2 was significantly upregulated in the superficial neurons of the dorsal horn after inflammatory injury. Up-regulated CCR2 further enhanced the NMDA currents induced by CCL2. This suggests that the endogenous CCL2 release and upregulation of CCR2 in the superficial layer of the dorsal horn after inflammatory injury is an important cause of neuronal excitability. We further confirmed that CCL2-induced inflammatory pain is blocked by the ERK inhibitor PD98059. In addition, we found that intrathecal injection of PD98059 reversed the inflammatory pain caused by CFA. These results suggest that CCL2 causes inflammatory pain by activating the ERK signaling pathway. Our experiments showed that the intracellular injection of an ERK inhibitor completely blocked the enhancement of NMDA currents induced by CCL2. ERK activation in dorsal horn neurons is nociception-specific and plays an important role in the induction of central sensitization [32, 33].

The NMDAR is a well-known subtype of voltage-gated ionotropic glutamate receptor [36–38]. NMDARs specifically allow Ca2+ to enter postsynaptic neurons; their continuous activation leads to extracellular Ca2+ entry into the cell [39]. Previous studies have shown that NMDARs are abundantly expressed in the pain pathway, where they are functionally expressed not only on the soma, but also on their peripheral and central processes [40–46]. Experimental data have shown that the PKA/Fyn/GluN2B...
pathway triggers the enhancement of GluN2B in the dorsal horn, leading to pain hypersensitivity [47]. Spinal GluN2B plays a key role in the development and maintenance of chronic pain [48]. Our study further confirmed that NMDA currents enhanced by CCL2/CCR2 through the ERK signal pathway were mainly mediated by the GluN2B subunit, which may further lead to synaptic plasticity in the dorsal horn.

It is well known that intraplantar injection of CFA causes upregulation of Cox-2 in spinal neurons and leads to inflammatory pain [49, 50]. The Cox-2 inhibitor NS-398 partly decreased the enhancement of NMDA-induced currents. These data suggest that CCL2 is involved in the development of central sensitization and inflammatory pain, in part through the induction of nociceptive genes such as Cox2, and Cox-2 inhibitors may be potential treatments for the development of central sensitization via CCL2/CCR2.

Thus, pERK can serve as a marker for central sensitization in spinal dorsal horn neurons [28] and inhibition of the CCL2/CCR2 pathway may reduce central sensitization. CCL2/CCR2 enhanced GluN2B function via activation of the downstream target ERK, suggesting that suppression of GluN2B in the dorsal horn reduces central sensitization. Our previous research showed that RS504393, a blocker of CCR2, inhibits the maintenance of LTP [16]. In this study, we further showed that RS504393 also inhibits the induction of LTP, and this effect is achieved by activating ERK. Therefore, by inhibiting the CCL2/CCR2 pathway or inhibiting the enhancement of ERK, central sensitization can be reduced, thereby reducing the occurrence of chronic pain.

**Acknowledgements** This work was supported by grants from the National Natural Science Foundation of China (81870867, 31671088, 31471059, and 81502102), and the Natural Science Foundation of Shaanxi Province, China (2019SF-071 and 2017ZDJC-01).

**Conflict of interest** The authors claim that there are no conflicts of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

**References**

1. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009, 139: 267–284.
2. Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 2014, 13: 533–548.
3. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med 2010, 16: 1248–1257.
4. Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol 2012, 12: 55–61.
5. White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A 2007, 104: 20151–20158.
6. Ji RR, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? Pain 2013, 154 Suppl 1: S10–28.
7. Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface. Nat Rev Immunol 2014, 14: 217–231.
8. Mennicken F, Maki R, de Souza EB, Quirion R. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Trends Pharmacol Sci 1999, 20: 73–78.
9. Miller RJ, Kostene W, Aparis E, Banisadr G, Biber K, Milligan ED, et al. Chemokine action in the nervous system. J Neurosci 2008, 28: 11792–11795.
10. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007, 10: 1361–1368.
11. Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA. Chemokines and pain mechanisms. Brain Res Rev 2009, 60: 125–134.
12. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmocol Ther 2010, 126: 56–68.
13. Jing PB, Cao DL, Li SS, Zhu M, Bai XQ, Wu XB, et al. Chemokine receptor CXCR3 in the spinal cord contributes to chronic itch in mice. Neurosci Bull 2018, 34: 54–63.
14. Liu XI, Liu T, Chen G, Wang B, Yu XL, Yin C, et al. TLR signaling adaptor protein MyD88 in primary sensory neurons contributes to persistent inflammatory and neuropathic pain and neuroinflammation. Sci Rep 2016, 6: 28188.

15. Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, et al. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci 2009, 29: 4096–4108.

16. Xie RG, Gao YJ, Park CK, Lu N, Luo C, Wang WT, et al. Spinal CCL2 promotes central sensitization, long-term potentiation, and inflammatory pain via CCR2: further insights into molecular, synaptic, and cellular mechanisms. Neurosci Bull 2018, 34: 13–21.

17. Zhang J, Shi XQ, Echeverry S, Mogil JS, De Koninck Y, Rivest S. Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci 2007, 27: 12396–12406.

18. Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, et al. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A 2003, 100: 7947–7952.

19. Chen G, Xie RG, Gao YJ, Xu ZZ, Zhao LX, Bang S, et al. Beta-arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain. Nat Commun 2016, 7: 12531.

20. Jewett GAE, Yavin D, Dhaliwal P, Whittaker T, Krupa J, et al. Arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain. Nat Commun 2016, 7: 12531.

21. Dansereau MA, Gosselin RD, Pohl M, Pommier B, Mechighel P, et al. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem 2008, 106: 757–769.

22. Knerlich-Lukoschus F, Juraschek M, Blomer U, Lucius R, Dansereau MA, et al. Two N-methyl-D-aspartate receptors in rat dorsal root ganglia. J Neurotrauma 2008, 25: 427–448.

23. Wu R, Zhang PA, Liu X, Zhou Y, Xu M, Jiang X, et al. Decreased mGluR5 and mGluR6 contribute to visceral hypersensitivity through post-transcriptional upregulation of CCL2 in rat dorsal root ganglia. Neurosci Bull 2019, 35: 79–801.

24. Ruscheweyh R, Wilder-Smith O, Drdla R, Liu XG, Sandkuhler J, et al. Identification of spinal circuits transmitting noxious information. J Neurosci 2011, 31: 18433–18438.

25. Ji RR, Baba H, Brenner GI, Woolf CJ. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 1999, 2: 1114–1119.

26. Araki K, Takeda F, Kwon S, Fujikura K, et al. Down-regulation of MAPK signaling in spinal cord astrocytes contributes to spinal neuronal injury. J Neurosci 2001, 21: 3771–3779.

27. Sun L, Margolis FL, Shipley MT, Lidow MS. Identification of a novel N-methyl-D-aspartate receptor antagonist. Neurosci Bull 2019, 35: 791–801.

28. Carlton SM, Edgerton FE, Lui LY, et al. Peripheral NMDA receptors revisited - Hope floats. Pain 2009, 146: 1–2.

29. Liu H, Wang H, Sheng M, Jan L, Jan YN, Higuchi M, et al. Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci 2007, 27: 12396–12406.

30. Cao DL, Zhang ZJ, Xie RG, Jiang BC, Ji RR, Gao YJ. Chemokine CXCL1 enhances inflammatory pain and increases NMMA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2. Exp Neurol 2014, 261: 328–336.